Canopy Growth's Stock Surges Amid Broader Market Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2024
0mins
Should l Buy CGC?
Source: Benzinga
Canopy Growth Corp's stock has surged by 18.32% as it crosses above the 5-day SMA, reflecting a significant price movement in the context of a strong market.
Despite the stock's recent rise, Canopy Growth continues to face severe challenges, including a staggering 99.6% decline over the past five years, intense market competition, and ongoing financial distress. The company has struggled to achieve profitability, with illegal sales making up a significant portion of the market, and it remains reliant on equity sales for capital, which has led to shareholder dilution.
The implications of these challenges suggest that while the stock may experience short-term gains, the long-term outlook remains grim, prompting investors to consider more financially stable alternatives in the cannabis sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 1.220
Low
1.03
Averages
2.52
High
5.90
Current: 1.220
Low
1.03
Averages
2.52
High
5.90
About CGC
Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intel CEO Tan Highlights Promising AI Future
- AI Business Growth: Intel (INTC) shares surged over 25% ahead of market open as CEO Lip-Bu Tan highlighted the company's pivot to AI, with financial outlook upgraded, projecting next quarter's revenue to rise from $13 billion to between $13.8 billion and $14.8 billion, indicating strong market demand and successful strategic transformation.
- Capacity Enhancement Plans: CFO David Zinsner stated that in response to soaring demand for data center processors, Intel is focused on rapidly increasing capacity to meet customer needs and avoid supply shortages, thereby enhancing its competitive position in the market.
- Strengthening Industry Position: Tan emphasized that as AI systems become more complex, Intel's CPUs remain the backbone of AI computing architecture, a trend that will further drive the company's market share and revenue growth in the future, showcasing its leadership in technological innovation.
- Positive Market Reaction: The market reacted enthusiastically to Intel's positive outlook and strong performance, reflecting investor confidence in the company's future development and further solidifying Intel's position in the tech industry.
See More
U.S. Marijuana Reclassification Impact Limited as Stocks Retreat
- Market Reaction: On Thursday, cannabis stocks retreated after early gains as investors reassessed the limited impact of the U.S. government's move to reclassify FDA-approved and state-licensed marijuana, with Cronos Group (CRON), Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), and OrganiGram Holdings (OGI) seeing declines between 7% and 14%.
- Policy Details: Acting Attorney General Todd Blanche announced on social media that FDA-approved marijuana and state-licensed marijuana would be rescheduled from Schedule I to Schedule III, although this measure applies specifically to certain FDA-approved products rather than the broader market, resulting in uneven benefits across the sector.
- Industry Response: FundCanna CEO Adam Stettner noted that medical operators could benefit from clearer federal alignment and potential tax relief, while companies focused on adult-use markets continue to face existing restrictions, including limited access to capital and regulatory fragmentation.
- Market Expectations: Todd Harrison, founding partner at CB1 Capital Management, indicated that while the rescheduling of medical cannabis takes effect immediately, the hearing for adult use is set for June, failing to meet investors' higher expectations and leading to a more pessimistic market sentiment.
See More
U.S. Places Medical Cannabis Products in Schedule III
- Policy Impact: The U.S. government's decision to place FDA-approved marijuana products and state-licensed medical cannabis programs into Schedule III is expected to facilitate clinical research and broaden treatment access, thereby enhancing the legitimacy of medical cannabis in modern healthcare.
- Tilray's Expansion Plans: Tilray is exploring participation in a federal pilot program run by the Center for Medicare and Medicaid Innovation, aiming to supply hemp-derived medical cannabis through cancer clinics, which is intended to improve services for underserved patients.
- Market Reaction Volatility: Although Tilray's stock surged by 19% following the policy announcement, it ultimately closed down 12%, reflecting investor concerns over the limited scope of the order, which also negatively impacted other cannabis companies' stock prices.
- Optimistic Industry Outlook: Roth Capital Partners views the partial rescheduling order as “extremely favorable,” potentially alleviating Section 280E tax restrictions, improving import and export prospects, and paving the way for eventual adult-use rescheduling, thus enhancing overall sector investability.
See More
DOJ Updates Marijuana Classification Policy
- Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
- Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
- Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
- Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
See More
Trump Signs Order Rescheduling Medical Marijuana, Boosting Cannabis Stocks
- Major Policy Shift: The order signed by Acting Attorney General Todd Blanche reclassifies state-licensed medical marijuana from the strict Schedule I to Schedule III, representing a significant policy shift for the U.S. government that is expected to enhance research and usage of medical marijuana.
- Tax Breaks and Research Facilitation: The new regulations allow state-licensed medical marijuana companies to deduct business expenses on federal taxes for the first time, while also easing access for researchers to obtain state-licensed marijuana products, thereby promoting industry legitimacy and growth.
- Positive Market Reaction: Following the announcement, shares of major Canadian cannabis producers such as Canopy Growth, Tilray, and Aurora Cannabis surged in premarket trading, indicating strong market optimism regarding the policy change, which may attract more investors to the sector.
- Future Outlook and Challenges: While the new regulations present opportunities for the medical marijuana industry, critics warn that legalization may lead to the emergence of more potent cannabis products, necessitating further research to ensure public health and safety.
See More
Canopy Growth Launches New Tweed Products for Summer Campaign
- Product Update: Canopy Growth launches a refreshed Tweed product lineup over the Victoria Day long weekend, featuring three new flower strains and the popular Quickies pre-rolls, aimed at attracting summer consumers.
- Transparent Packaging: The introduction of window bags allows consumers to clearly see the products they are purchasing, enhancing visibility and appeal while improving potency and pricing, making it more competitive in the market.
- Market Positioning: The updates to Tweed reflect consumer and budtender feedback, emphasizing the company's commitment to consumer needs and enhancing brand loyalty through improved product quality and pricing strategies.
- Future Development: Canopy Growth plans to introduce a new milled format in summer 2026, further expanding its product line and demonstrating the company's commitment to continuous innovation and meeting market demands.
See More
Intel CEO Tan Highlights Promising AI Future
- AI Business Growth: Intel (INTC) shares surged over 25% ahead of market open as CEO Lip-Bu Tan highlighted the company's pivot to AI, with financial outlook upgraded, projecting next quarter's revenue to rise from $13 billion to between $13.8 billion and $14.8 billion, indicating strong market demand and successful strategic transformation.
- Capacity Enhancement Plans: CFO David Zinsner stated that in response to soaring demand for data center processors, Intel is focused on rapidly increasing capacity to meet customer needs and avoid supply shortages, thereby enhancing its competitive position in the market.
- Strengthening Industry Position: Tan emphasized that as AI systems become more complex, Intel's CPUs remain the backbone of AI computing architecture, a trend that will further drive the company's market share and revenue growth in the future, showcasing its leadership in technological innovation.
- Positive Market Reaction: The market reacted enthusiastically to Intel's positive outlook and strong performance, reflecting investor confidence in the company's future development and further solidifying Intel's position in the tech industry.
See More
U.S. Marijuana Reclassification Impact Limited as Stocks Retreat
- Market Reaction: On Thursday, cannabis stocks retreated after early gains as investors reassessed the limited impact of the U.S. government's move to reclassify FDA-approved and state-licensed marijuana, with Cronos Group (CRON), Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), and OrganiGram Holdings (OGI) seeing declines between 7% and 14%.
- Policy Details: Acting Attorney General Todd Blanche announced on social media that FDA-approved marijuana and state-licensed marijuana would be rescheduled from Schedule I to Schedule III, although this measure applies specifically to certain FDA-approved products rather than the broader market, resulting in uneven benefits across the sector.
- Industry Response: FundCanna CEO Adam Stettner noted that medical operators could benefit from clearer federal alignment and potential tax relief, while companies focused on adult-use markets continue to face existing restrictions, including limited access to capital and regulatory fragmentation.
- Market Expectations: Todd Harrison, founding partner at CB1 Capital Management, indicated that while the rescheduling of medical cannabis takes effect immediately, the hearing for adult use is set for June, failing to meet investors' higher expectations and leading to a more pessimistic market sentiment.
See More
U.S. Places Medical Cannabis Products in Schedule III
- Policy Impact: The U.S. government's decision to place FDA-approved marijuana products and state-licensed medical cannabis programs into Schedule III is expected to facilitate clinical research and broaden treatment access, thereby enhancing the legitimacy of medical cannabis in modern healthcare.
- Tilray's Expansion Plans: Tilray is exploring participation in a federal pilot program run by the Center for Medicare and Medicaid Innovation, aiming to supply hemp-derived medical cannabis through cancer clinics, which is intended to improve services for underserved patients.
- Market Reaction Volatility: Although Tilray's stock surged by 19% following the policy announcement, it ultimately closed down 12%, reflecting investor concerns over the limited scope of the order, which also negatively impacted other cannabis companies' stock prices.
- Optimistic Industry Outlook: Roth Capital Partners views the partial rescheduling order as “extremely favorable,” potentially alleviating Section 280E tax restrictions, improving import and export prospects, and paving the way for eventual adult-use rescheduling, thus enhancing overall sector investability.
See More
DOJ Updates Marijuana Classification Policy
- Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
- Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
- Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
- Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
See More
Trump Signs Order Rescheduling Medical Marijuana, Boosting Cannabis Stocks
- Major Policy Shift: The order signed by Acting Attorney General Todd Blanche reclassifies state-licensed medical marijuana from the strict Schedule I to Schedule III, representing a significant policy shift for the U.S. government that is expected to enhance research and usage of medical marijuana.
- Tax Breaks and Research Facilitation: The new regulations allow state-licensed medical marijuana companies to deduct business expenses on federal taxes for the first time, while also easing access for researchers to obtain state-licensed marijuana products, thereby promoting industry legitimacy and growth.
- Positive Market Reaction: Following the announcement, shares of major Canadian cannabis producers such as Canopy Growth, Tilray, and Aurora Cannabis surged in premarket trading, indicating strong market optimism regarding the policy change, which may attract more investors to the sector.
- Future Outlook and Challenges: While the new regulations present opportunities for the medical marijuana industry, critics warn that legalization may lead to the emergence of more potent cannabis products, necessitating further research to ensure public health and safety.
See More
Canopy Growth Launches New Tweed Products for Summer Campaign
- Product Update: Canopy Growth launches a refreshed Tweed product lineup over the Victoria Day long weekend, featuring three new flower strains and the popular Quickies pre-rolls, aimed at attracting summer consumers.
- Transparent Packaging: The introduction of window bags allows consumers to clearly see the products they are purchasing, enhancing visibility and appeal while improving potency and pricing, making it more competitive in the market.
- Market Positioning: The updates to Tweed reflect consumer and budtender feedback, emphasizing the company's commitment to consumer needs and enhancing brand loyalty through improved product quality and pricing strategies.
- Future Development: Canopy Growth plans to introduce a new milled format in summer 2026, further expanding its product line and demonstrating the company's commitment to continuous innovation and meeting market demands.
See More
